These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 18456464)

  • 21. Cutaneous leishmaniasis treatment.
    Minodier P; Parola P
    Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
    Berman J
    Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
    [No Abstract]   [Full Text] [Related]  

  • 23. Post-kala-azar dermal Leishmaniasis and uveitis in an HIV-positive patient.
    Ramos A; Cruz I; Muñez E; Salas C; Fernández A; Alvarez-Espejo T
    Infection; 2008 Mar; 36(2):184-6. PubMed ID: 18327683
    [No Abstract]   [Full Text] [Related]  

  • 24. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
    J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
    Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
    Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 27. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
    Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
    Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comment on: Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    Collazos J
    J Antimicrob Chemother; 2008 Feb; 61(2):466-7; author reply 467. PubMed ID: 18077312
    [No Abstract]   [Full Text] [Related]  

  • 29. [Importance of drug carriers in the treatment of visceral leishmaniasis].
    Fusai T; Durand R; Boulard Y; Paul M; Bories C; Rivollet D; Houin R; Deniau M
    Med Trop (Mars); 1995; 55(1):73-8. PubMed ID: 7637615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Visceral leishmaniasis: clinical sensitivity and resistance to various therapeutic agents].
    Janvier F; Morillon M; Olliaro P
    Med Trop (Mars); 2008 Feb; 68(1):89-101. PubMed ID: 18478781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
    Borrelli P; Imperato A; Murdaca G; Scudeletti M
    Ann Ital Med Int; 2000; 15(2):169-71. PubMed ID: 10920508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
    Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
    Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
    Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of visceral leishmaniasis.
    Ozsoylu S
    Turk J Pediatr; 2003; 45(3):280. PubMed ID: 14696814
    [No Abstract]   [Full Text] [Related]  

  • 35. Acute renal failure due to visceral leishmaniasis by Leishmania infantum successfully treated with a single high dose of liposomal amphotericin B.
    Beltrame A; Arzese A; Camporese A; Rorato G; Crapis M; Tarabini-Castellani G; Boscutti G; Pizzolitto S; Calianno G; Matteelli A; Di Muccio T; Gramiccia M; Viale P
    J Travel Med; 2008; 15(5):358-60. PubMed ID: 19006511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
    Olliaro P; Sundar S
    Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
    Vigna E; De Vivo A; Gentile M; Morelli R; Lucia E; Mazzone C; Recchia AG; Vianelli N; Morabito F
    Transpl Infect Dis; 2010 Oct; 12(5):428-31. PubMed ID: 20534035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
    Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
    J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An unwelcome synergy: leishmaniasis and HIV.
    Colasanti J; Altamirano J; Espinoza L
    Am J Med; 2013 Feb; 126(2):114-6. PubMed ID: 23331437
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of visceral leishmaniasis.
    Sundar S
    Med Microbiol Immunol; 2001 Nov; 190(1-2):89-92. PubMed ID: 11770119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.